🚀
Enjoy a 7-Day Free Trial Thru May 03, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
NGM Biopharmaceuticals Inc (NAS:NGM)
News
NGM Biopharmaceuticals Inc
NAS
:NGM (USA) Â
$ 1.54
0 (0%)
08:08 PM EST
P/E:
At Loss
P/B:
0.86
Market Cap:
$ 128.53M
Enterprise V:
$ -36.13M
Volume:
-
Avg Vol (2M):
1.42M
Warning! GuruFocus detected 5 Severe warning signs with NGM.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
-
Market Cap $:
128.53M
PE Ratio:
At Loss
Avg Vol (2M):
1.42M
Enterprise Value $:
-36.13M
PB Ratio:
0.86
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocks™
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
NGM Biopharmaceuticals Inc (NAS:NGM) Stock News, Headlines & Updates
NGM Biopharmaceuticals Inc Stock News from GuruFocus
Total 114
1
2
3
Mar 19, 2024
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
GlobeNewswire
•
5:00pm
Mar 13, 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM
PRNewswire
•
1:00pm
Mar 05, 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, MDC, NGM, JNPR
PRNewswire
•
4:00pm
Feb 27, 2024
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - AA, NGM, MDC, KAMN
PRNewswire
•
7:00pm
Feb 26, 2024
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
Business Wire
•
11:00am
Feb 08, 2024
NGM Biopharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Jefferies Healthcare Conference Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc CATALINA Topline Results Call Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc R&D Event (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc R&D Event (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc Virtual R&D Event Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc R&D Day (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc Phase 2b ALPINE 2/3 Study Results Call Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc R&D Day Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc Annual Shareholders Meeting Transcript
GuruFocus Research
•
11:56pm
NGM Biopharmaceuticals Inc to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH Call Transcript
GuruFocus Research
•
11:56pm
Nov 02, 2023
NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial Results
GuruFocus Research
•
5:42pm
Oct 11, 2023
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
Marketwired
•
4:00pm
Aug 03, 2023
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
Marketwired
•
4:00pm
Mar 01, 2023
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
sperokesalga
•
8:00am
Jan 12, 2023
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
Stock market mentor
•
7:00am
Jan 09, 2023
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
Stock market mentor
•
8:00am
Dec 13, 2022
NGM Bio Gives Presentation Featuring Preclinical Characterization of NGM936 at 2022 ASH Annual Meeting
Value_Insider
•
6:00pm
Dec 08, 2022
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting
Value_Insider
•
6:00pm
Nov 07, 2022
NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting
Value_Insider
•
7:00am
Nov 04, 2022
RHO CAPITAL PARTNERS INC Cuts Portfolio Down to Size in 3rd Quarter
GuruFocus Research
•
1:00pm
NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting
Value_Insider
•
7:00am
Nov 03, 2022
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
Value_Insider
•
12:00pm
Oct 17, 2022
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Value_Insider
•
7:00am
Oct 16, 2022
NGM Bio to Host Conference Call to Discuss Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Value_Insider
•
4:00pm
Aug 15, 2022
NGM Bio Announces Presentations Featuring Updated Findings from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the European Society of Medical Oncology (ESMO) Annual Congress and the Ongoing Phase 1b Trial o
PurpleRose
•
7:00am
Jul 10, 2022
NGM Bio Appoints Siobhan Nolan Mangini to President and Chief Financial Officer
GuruFocusNews
•
7:38am
Total 114
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news